THN391 is named as an intervention in 2 current clinical trials in our UK, Netherlands and Australia registers. 1 is recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is Therini Bio, Inc (1). The most-studied condition is Alzheimer Disease, Early Onset.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
NCT06701721 · ClinicalTrials.gov ↗ · Diabetic Macular Edema, Diabetic Retinopathy
|
Phase 1 | Recruiting | Therini Bio Pty Ltd | Australia |
|
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730 · ClinicalTrials.gov ↗ · Alzheimer Disease, Early Onset
|
Phase 1 | Active, closed | Therini Bio, Inc | UK, Netherlands |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Therini Bio, Inc | 1 |
| Therini Bio Pty Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 0 |
| Clinical trials in Netherlands | 1 | 0 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, Netherlands and Australia registers name THN391 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Therini Bio, Inc (1) and Therini Bio Pty Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how THN391 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how THN391 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists THN391 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.